Pharmacological activation of the GABAergic system does not affect GH and PRL release in acromegaly.
An extensive hypothalamic neurotransmitter impairment has been proposed in acromegaly. However, at the moment, the hypothalamic GABAergic system has been little investigated in this disorder. Since GABA has been shown to modulate growth hormone (GH) and prolactin (PRL) secretion in human subjects, it seemed reasonable to investigate hypothalamic GABAergic functioning through the assessment of basal GH and PRL responses to pharmacological activation of this system. 800 mg of sodium valproate (SV), a drug with GABA facilitating properties, were administered orally to 7 acromegalic patients and 9 healthy volunteers. Blood samples were collected before and after the drug administration for the measurement of plasma GH and PRL levels. SV induced a clear-cut rise in basal GH and a decrease in basal PRL in healthy subjects, but it did not induce any change in the basal levels of these hormones in acromegalics. These results suggest that the response of GH and PRL to SV in acromegaly is qualitatively different from normal controls.
Orio
F
F
Department of Endocrinology, General Hospital of Eboli, Salerno, Italy.
Iovino
M
M
Monteleone
P
P
Agrusta
M
M
Steardo
L
L
Lombardi
G
G
D000172:Acromegaly / Q000503:physiopathology*; D000328:Adult; D005640:Follicle Stimulating Hormone / Q000097:blood; D013006:Growth Hormone / Q000378:metabolism*; D006801:Humans; D007031:Hypothalamus / Q000187:drug effects; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008875:Middle Aged; D011388:Prolactin / Q000378:metabolism*; D011963:Receptors, GABA-A / Q000187:drug effects*; D013972:Thyrotropin / Q000097:blood; D014635:Valproic Acid / Q000494:pharmacology*
D011963:Receptors, GABA-A; D014635:Valproic Acid; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D013972:Thyrotropin; D013006:Growth Hormone